Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices
about
Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and ManagementToxicity of amphetamines: an updateExcretion of Delta9-tetrahydrocannabinol in sweatRecent developments in sweat analysis and its applicationsScreening for amphetamine and amphetamine-type drugs in doping analysis by liquid chromatography/mass spectrometry.Development and validation of a disk solid phase extraction and gas chromatography-mass spectrometry method for MDMA, MDA, HMMA, HMA, MDEA, methamphetamine and amphetamine in sweat.Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatumPrevalence of legal and illegal stimulating agents in sports.A mechanistic insight into 3,4-methylenedioxymethamphetamine ("ecstasy")-mediated hepatotoxicity.Consumption of palatable food decreases the anorectic effects of serotonergic, but not dopaminergic drugs in baboonsRole of endogenous release of norepinephrine in muscle spasms after chronic spinal cord injuryThe amphetamine response moderates the relationship between negative emotionality and alcohol useInterpretation of oral fluid tests for drugs of abuse.Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration.Ecstasy (MDMA) and oral health.A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.Bottoms up: methamphetamine toxicity from an unusual route.Chronic cocaine but not chronic amphetamine use is associated with perseverative responding in humansMethylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage.Collection of biological samples in forensic toxicology.Correlation between blood and oral fluid psychoactive drug concentrations and cognitive impairment in Driving Under the Influence of Drugs.Medico-legal assessment of methamphetamine and amphetamine serum concentrations-what can we learn from survived intoxications?The risky cocktail: what combination effects can we expect between ecstasy and other amphetamines?Smaller amygdala and medial prefrontal cortex predict escalating stimulant use.Comparison of 3 Derivatization Methods for the Analysis of Amphetamine-Related Drugs in Oral Fluid by Gas Chromatography-Mass SpectrometrySweat testing for the detection of atomoxetine from paediatric patients with attention deficit/ hyperactivity disorder: application to clinical practice.Long-term follow-up analysis of zolpidem in fingernails after a single oral dose.Family history of alcoholism and response to amphetamine: sex differences in the effect of risk.Mixtures of 3,4-methylenedioxymethamphetamine (ecstasy) and its major human metabolites act additively to induce significant toxicity to liver cells when combined at low, non-cytotoxic concentrations.Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.Interaction and Transport of Methamphetamine and its Primary Metabolites by Organic Cation and Multidrug and Toxin Extrusion Transporters.Determination of ethyl glucuronide in nails by liquid chromatography tandem mass spectrometry as a potential new biomarker for chronic alcohol abuse and binge drinking behaviorNail analysis for the detection of drugs of abuse and pharmaceuticals: a review
P2860
Q21260315-924F2EE8-EFEE-4C75-9FE0-B734A0A63597Q22252568-4C1E4E0E-84AF-4C00-8FB8-5F999398C36FQ22252794-4F25B48E-64FA-497A-BB26-7DA71814937CQ24648033-B24EADDD-8B87-43DE-885E-2A0415D5B92EQ26849651-69130EA5-56E0-4715-99C9-91E700D9E716Q33434788-8DEBDFBD-6032-4B21-9C6E-21E4AAC3D72BQ33906745-E76D3BDF-84B7-4CB4-963E-355D4EC77E9BQ34051713-A49855A3-E9B7-461A-928F-8328D9E76B51Q34177175-21D92B32-8466-4F85-BD18-72120D13452FQ34239110-D3D9B622-058C-4EB1-BB5C-6E7A2E1EF8E4Q35023998-5E1B2A8F-189B-46F3-94D3-A6FBB5E21316Q36227595-B0423B07-6EFD-4B4F-AEE2-70EB7C8BA3A0Q36585643-D91C2F17-07D2-4037-BECA-10F44243D21FQ36748917-221673C7-52BB-47DC-82AB-09A72B63E6D6Q36992670-BA125615-9153-4B23-A21C-D3A48027B330Q37082483-B4C6AE13-ABF7-4277-9A8F-926096B2888BQ37104132-4C671B00-D41A-4DCB-ACCD-B30C688B5312Q37166993-27FD7F6A-DC17-4751-9C38-9554CC570AE3Q37202338-24F5AE4A-E764-416E-90DC-35AA3598F6D6Q37685508-0E08A7FD-6B82-4B30-995F-C1D97F574167Q37771033-AEAAC331-4949-4BF3-8436-E0FCEB3B2F2EQ38605437-CA58155D-B4D1-4BB4-BDC6-B9C4FA77044AQ38783152-A3241969-364E-4C63-9029-44D65D063178Q39273495-64432A78-87BE-427E-9E65-922903F74BD3Q40942514-A773F295-FF79-4B7D-BE57-C2C274E0EF4CQ41544518-D9329BC4-974D-4091-B9D8-FC25F04B839EQ43943982-C5985616-8DF4-4EC0-813C-926B7510B158Q44297032-0D0272BB-78FC-4B07-9C17-523D6693C718Q46493890-C7BC1F6D-380E-414E-8E9D-B3116C0AC1BBQ51218198-6D17E490-1A45-4526-B718-936CB2E44ACAQ51482811-141D9487-821A-457C-B3DB-EB9DE35796CCQ52675161-5C4AC13E-CB62-4B87-BD07-002CFCE81399Q56775284-CF982481-ED36-4733-8478-ADBEB48A8F47Q57523850-115EB63D-72CD-438D-93EB-76804A384654
P2860
Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices
description
2004 nî lūn-bûn
@nan
2004 թուականին հրատարակուած գիտական յօդուած
@hyw
2004 թվականին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Clinical pharmacokinetics of a ...... and non-conventional matrices
@ast
Clinical pharmacokinetics of a ...... and non-conventional matrices
@en
Clinical pharmacokinetics of a ...... and non-conventional matrices
@nl
type
label
Clinical pharmacokinetics of a ...... and non-conventional matrices
@ast
Clinical pharmacokinetics of a ...... and non-conventional matrices
@en
Clinical pharmacokinetics of a ...... and non-conventional matrices
@nl
prefLabel
Clinical pharmacokinetics of a ...... and non-conventional matrices
@ast
Clinical pharmacokinetics of a ...... and non-conventional matrices
@en
Clinical pharmacokinetics of a ...... and non-conventional matrices
@nl
P2093
P1476
Clinical pharmacokinetics of a ...... and non-conventional matrices
@en
P2093
Magí Farré
Mónica Navarro
Piergiorgio Zuccaro
Roberta Pacifici
P304
P356
10.2165/00003088-200443030-00002
P407
P577
2004-01-01T00:00:00Z
P5875
P6179
1043899982